Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Christy J. Wilson

Christy J. Wilson

Sr. Director, Pharma and Biotech Segment

Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter
Website:

About the author: Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution. Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market. Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).

Posts by Christy J. Wilson

Reducing the Risk of Late-Stage Failure with In Silico Modeling

Posted on June 15th, 2016 in Pharma R&D

In silico modeling is arguably one of the hottest trends in life sciences R&D today. We know that bringing drug discovery to the desktop impacts cost. (more…)

Introducing ‘The Hive’

Posted on May 4th, 2016 in Pharma R&D

Fifty-four percent. That’s the percentage of “all active drugs” sourced via open innovation models for the 12 largest biopharma company pipelines in 2014. (more…)

“If you gave the same NCE to two different companies……”

Posted on March 24th, 2016 in Pharma R&D

You might think this is the opening line for a riddle, but in fact it forms the basis of IDEA Pharma’s Productive Innovation Index (PII for short), an annual ranking of the top 30 biopharmaceutical companies (more…)

R&D? S&D? It’s About Science

Posted on February 9th, 2016 in Pharma R&D

Last month’s announcement that industry giants AstraZeneca, GSK, and Johnson & Johnson had teamed up with three well-regarded UK universities –Imperial College London, University College London, and University of (more…)

  1. 1
  2. …
  3. 11
  4. 12
  5. 13
  6. 14